CellCentric is beginning clinical testing of CCS1477, a novel, first-in-class drug for late-stage prostate cancer, following regulatory clearance in the UK.
The clinical trial has been initiated following regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA). Approximately 120 patients will be recruited to assess CCS1477’s tolerability and efficacy (Phase Ib/IIa). The drug will be tested as a monotherapy and also in combination with Zytiga as well as Xtandi.
With over 80,000 potential patients each year, there is a growing need for ground-breaking treatments for late-stage prostate cancer.
XenoGesis has supported the DMPK aspects of the project since 2014. This ultimately led to the selection of CCS1477 based on the in vitro and in vivo properties measured by XenoGesis and the resulting positive prediction of human PK and dose.
This represents the seventh client compound to reach the clinic, where XenoGesis has provided the DMPK support and advice.